Skip to content
HowShorted

Co-Diagnostics, Inc. short interest in 2023

In 2023, Co-Diagnostics, Inc.'s disclosed short interest ran from 4.14% of shares outstanding on 13 Jan 2023 to 2.07% on 29 Dec 2023, a change of -2.07 percentage points. The year's high was 5.03% on 31 Jan 2023 and its low 1.59% on 31 Oct 2023, averaging 2.68% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.55 days on 31 Oct 2023. Full history: Co-Diagnostics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Co-Diagnostics, Inc. in 2023

2023 in figures

Start of year
4.14% (13 Jan 2023)
End of year
2.07% (29 Dec 2023)
Change
-2.07 pp
High
5.03% (31 Jan 2023)
Low
1.59% (31 Oct 2023)
Average
2.68%
Highest days to cover
17.55 (31 Oct 2023)
SEC filings marked
8

Every report in 2023

Co-Diagnostics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20234.14%15.40
31 Jan 20235.03%12.19
15 Feb 20233.75%11.59
28 Feb 20234.23%16.90
15 Mar 20233.37%15.65
31 Mar 20233.47%3.5110-K filed, results (8-K)
14 Apr 20232.77%5.35
28 Apr 20232.69%8.27
15 May 20232.34%7.0210-Q filed, results (8-K)
31 May 20231.94%6.47
15 Jun 20232.27%9.19
30 Jun 20232.18%13.62
14 Jul 20232.48%6.29
31 Jul 20232.42%2.71
15 Aug 20232.60%6.2610-Q filed, results (8-K)
31 Aug 20232.60%8.28
15 Sep 20231.89%7.17
29 Sep 20232.29%10.58
13 Oct 20232.27%13.82
31 Oct 20231.59%17.55
15 Nov 20232.18%7.9210-Q filed, results (8-K)
30 Nov 20232.16%4.66
15 Dec 20231.62%7.33
29 Dec 20232.07%2.55

See also: Co-Diagnostics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.